Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.

StrategyPharma & Healthcare

Stella Pharma wins Japan approval for its BNCT drug in recurrent meningioma, with insurance cover expected from March

Stella Pharma's boron neutron capture therapy drug has been approved in Japan for recurrent meningioma, a wider label than the high-grade trial population, but insurance cover for the neutron irradiation is expected only from 1 March 2027.

By Tokyo Brief DeskNov 16, 2026, 20:49 JST2 min readSTELLA PHARMA CORPORATION4888
Illustration of a radiotherapy treatment room with an infusion bag and abstract beam lines converging on a point.

Stella Pharma said on 16 November 2026 that it has received a partial-change approval to the marketing authorisation for its boron neutron capture therapy (BNCT) drug, a 9000mg/300mL infusion bag, adding "recurrent meningioma" as an indication. The company describes this as the first approval in Japan of a drug for that indication. That first-in-Japan claim is the company's own. Earlier Tokyo Brief coverage

A wider label than the trial

The application rests on an investigator-initiated phase II randomised trial run at Osaka Medical and Pharmaceutical University in recurrent high-grade meningioma, meaning WHO Grade 2 or 3. The approved wording is not limited to those patients. It covers recurrent meningioma more broadly. The company says this should widen the pool of patients treatable with BNCT.

The company's release adds a limit on use: where curative treatment such as surgery is possible, that takes priority, and the indication is to be judged against each patient's condition and treatment history.

What the trial showed

The trial compared BNCT using the drug and a BNCT treatment system against best supportive care. Median progression-free survival was 14.4 months in the BNCT group and 1.4 months in the comparison group, a statistically significant difference, according to the company, which cites its 21 October 2026 announcement. The company says the drug received orphan designation in September 2024 and was assessed as a priority review item in February 2026.

Reimbursement is the next step

Approval does not settle payment. Stella Pharma says the relevant bodies are due to take the procedures needed to bring the technical fee for neutron irradiation into insurance coverage, which it expects to start on 1 March 2027. Until then, treatment is planned under the evaluation-treatment scheme, according to the company.

Stella Pharma expects the effect on results for the year ending March 2027 to be minor, and says the approval should contribute to BNCT business growth in the medium to long term. The company says the indication follows head and neck cancer as a new BNCT drug indication, and it ranks indication expansion alongside treatment-site expansion and overseas rollout as its growth pillars.